Viridian Therapeutics to Participate in the JMP Securities Life Sciences Conference

Rhea-AI Summary

Viridian Therapeutics (Nasdaq: VRDN) announced that Jonathan Violin, Ph.D., its CEO, will participate in a fireside chat at the JMP Securities Life Sciences Conference on June 17, 2021, at 2:30 p.m. ET. This virtual event will focus on the company’s advancements in biopharmaceuticals for serious diseases. Interested parties can access the webcast on Viridian's website, with a replay available for 90 days post-event. Viridian is developing VRDN-001, targeting the debilitating autoimmune disease TED, which can lead to vision impairment.

BOULDER, Colo., June 10, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies, today announced that Jonathan Violin, Ph.D., President and Chief Executive Officer of Viridian, will participate in a fireside chat at the virtual JMP Securities Life Sciences Conference taking place June 16 – 17, 2021.

Event:	The JMP Securities Life Sciences Conference
Date:	Thursday, June 17
Fireside Chat Time:	2:30 p.m. ET

Webcast information for these events will be accessible on the Events page under the Investors section of the Viridian Therapeutics website at www.viridiantherapeutics.com. A replay of the fireside chat will be archived on the website and available for approximately 90 days following the live event.

About Viridian Therapeutics

Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies. Viridian’s most advanced program, VRDN-001, is an anti-IGF-1R monoclonal antibody in development for TED, a debilitating auto-immune disease that causes inflammation and fibrosis within the orbit of the eye which can cause double vision, pain, and potential blindness. Patients with severe disease often require multiple remedial surgeries to the orbit, eye muscles, and eyelids. Viridian is based in Boulder, Colorado, and Waltham, Massachusetts. Learn more about Viridian and its programs at https://www.viridiantherapeutics.com/.

Follow us on Twitter @ViridianThera and on LinkedIn.

Viridian Contacts:
Investors:
Dan Ferry
LifeSci Advisors
617-430-7576
IR@viridiantherapeutics.com 

Media:
Darby Pearson
Verge Scientific Communications
703-587-0831
PR@viridiantherapeutics.com 

FAQ

When is the fireside chat for Viridian Therapeutics at the JMP Securities Life Sciences Conference?

The fireside chat will take place on June 17, 2021, at 2:30 p.m. ET.

Who is representing Viridian Therapeutics at the conference?

Jonathan Violin, Ph.D., President and CEO of Viridian Therapeutics, will represent the company.

Where can I find the webcast for the Viridian Therapeutics conference?

The webcast for the event can be found on the Events page under the Investors section of the Viridian Therapeutics website.

What is VRDN-001 being developed for?

VRDN-001 is an anti-IGF-1R monoclonal antibody in development for Thyroid Eye Disease (TED).

How long will the replay of the fireside chat be available?

The replay of the fireside chat will be available for approximately 90 days following the live event.